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evolution to a bilateral tonic-clonic seizure. FS had posterior-temporal/occipital onset, slowly spreading
and sometimes migrating between hemispheres. Brain MRI showed progressive parenchymal atrophy
and restriction of the optic radiations. CONCLUSIONS developmental and epileptic encephalopathy has
strikingly consistent electroclinical features, suggesting a global progressive brain dysfunction primarily
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Abstract
Objective
To delineate the electroclinical features of SCN8A infantile developmental and epileptic en-
cephalopathy (EIEE13, OMIM #614558).
Methods
Twenty-two patients, aged 19 months to 22 years, underwent electroclinical assessment.
Results
Sixteen of 22 patients hadmildly delayed development since birth. Drug-resistant epilepsy started at
a median age of 4 months, followed by developmental slowing, pyramidal/extrapyramidal signs
(22/22), movement disorders (12/22), cortical blindness (17/22), sialorrhea, and severe gastro-
intestinal symptoms (15/22), worsening during early childhood and plateauing at age 5 to 9 years.
Death occurred in 4 children, following extreme neurologic deterioration, at 22months to 5.5 years.
Nonconvulsive status epilepticus recurred in 14 of 22 patients. The most eﬀective antiepileptic
drugs were oxcarbazepine, carbamazepine, phenytoin, and benzodiazepines. EEG showed back-
ground deterioration, epileptiform abnormalities with a temporo-occipital predominance, and
posterior delta/beta activity correlating with visual impairment. Video-EEG documented focal
seizures (FS) (22/22), spasm-like episodes (8/22), cortical myoclonus (8/22), and myoclonic
absences (1/22). FS typically clustered and were prolonged (<20 minutes) with (1) cyanosis,
hypomotor, and vegetative semiology, sometimes unnoticed, followed by (2) tonic-vibratory and
(3) (hemi)-clonic manifestations ± evolution to a bilateral tonic-clonic seizure. FS had posterior-
temporal/occipital onset, slowly spreading and sometimes migrating between hemispheres. Brain
MRI showed progressive parenchymal atrophy and restriction of the optic radiations.
Conclusions:
SCN8A developmental and epileptic encephalopathy has strikingly consistent electroclinical features,
suggesting a global progressive brain dysfunction primarily aﬀecting the temporo-occipital regions.
Both uncontrolled epilepsy and developmental compromise contribute to the profound impairment
(increasing risk of death) during early childhood, but stabilization occurs in late childhood.
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SCN8A encodes the pore-forming voltage-gated sodium
channel subunit Nav1.6, which is widely expressed in the
brain.1 Pathogenic variants in SCN8A result in impaired
channel inactivation, causing neuronal hyperexcitability,
seizures, and neurocognitive problems.2
In humans, pathogenic SCN8A variants are associated with
a wide spectrum of epilepsy phenotypes, spanning from benign
familial infantile seizures3,4 to mild-to-severe developmental and
epileptic encephalopathies.5–10 Early infantile epileptic enceph-
alopathy type 13 (EIEE13, OMIM #614558) is a recently rec-
ognized syndrome caused by de novo SCN8A missense
variants.2,11 Clinical features include developmental impairment,
which is usually severe, although at times milder, pyramidal and
extrapyramidal signs, and epilepsy.9 Seizures start before 18
months of age and are intractable, although may improve with
sodium channel–blocking antiepileptic drugs (AEDs). Multiple
seizure types occur, including focal seizures (FS), generalized
seizures, and epileptic spasms.12 In a previous report, we de-
scribed a heterogeneous spectrum of epilepsies related to variants
in SCN8A and emphasized the peculiar interictal EEG abnor-
malities in some patients.9 SUDEP (sudden unexpected death in
epilepsy) is reported in approximately 10% of cases.2,9,10,13
Since the same SCN8A variant can lead to diﬀerent clinical
scenarios,13 phenotyping is crucial in informing prognosis.
With this study, we sought to further characterize the inter-
ictal and ictal electroclinical phenotype in a large homoge-
neous cohort of patients with severe SCN8A developmental
and epileptic encephalopathy (SCN8A-DEE).
Methods
Through an international collaboration including clinical ep-
ilepsy centers in Europe, the United States, and Australia, we
collected patients with epileptic encephalopathy due to
SCN8A variants. Clinical information was collected retro-
spectively and prospectively by face-to-face interviews with
patients and their families and from clinical charts. The re-
ferring clinicians provided a detailed phenotyping table,
contacting the families in case of missing information.
Neurophysiologic and imaging investigations
Video-EEG recordings were available for 20 of 22 patients at
epilepsy onset and all patients at follow-up. EEGs were
obtained by a digital acquisition system, placing scalp elec-
trodes according to the 10-20 international system. Selected
patients underwent video-polygraphic investigations (EEG,
ECG, and EMG traces). In 20 patients, ictal EEG recordings
were available, and for the remaining 2 patients, EEG reports
were obtained. A single epileptologist with EEG expertise
(E.G.) reviewed 97 EEGs (1–12 EEGs per patient, with a
follow-up of 10–56 months, including long-term monitoring
video-EEGs) for background activity, interictal epileptiform
abnormalities, ictal EEGdischarges, and clinical manifestations.
For 8 patients, an overnight video-EEG was available, and
a visual assessment of sleep macrostructure was performed. In
selected patients (6, 15, and 17), the interictal and ictal EEG
underwent oﬄine analysis, namely, source analysis and dipole
localization using the brain electrical source analysis program
(BESA GmbH, Gra¨felﬁng, Germany). Electroretinograms, vi-
sual evoked potentials, somatosensory evoked potentials, and
nerve conduction studies were performed in 4, 7, 4, and 2
patients, respectively. Brain MRI data were obtained from all
patients (1–4 scans each), including MRI spectroscopy in 6.
Standard protocol approvals, registrations,
and patient consents
Written informed consent, including authorization for re-
production of video images, was obtained for all patients and
family members where necessary. Patient data were collected
according to guidelines of their country’s research ethics
committee.
Data availability
Anonymized data that support the ﬁndings of this study are
available from the corresponding author (E.G.) on reasonable
request. Not all of the data are publicly available because they
contain information that could compromise children’s privacy
and their family consent.
Results
We collected the electroclinical data of 17 unpublished and 5
previously published patients. The patients with published
data had previously been described in less detail.
The cohort included 11 males and 11 females whose ages
ranged from 19 months to 22 years (table 1). None of the
patients had a similarly aﬀected family member; however, 6
patients (4, 6, 11, 15, 20, 21) had a family history of epileptic
seizures in 1 or 2 ﬁrst- or second-degree relatives who did not
carry an SCN8Amutation. All but one (patient 20) were born
at term; none had experienced a perinatal insult.
Epilepsy
Median age at epilepsy onset was 4 months (range: 0.5–36
months) (table 1). One child (patient 3) had increased fetal
movements, reminiscent of seizures, and one (patient 15) had
Glossary
AED = antiepileptic drug; DEE = developmental and epileptic encephalopathy; EIEE13 = early infantile epileptic
encephalopathy type 13; FS = focal seizures; NCSE = nonconvulsive status epilepticus; SUDEP = sudden unexpected death in
epilepsy; TCS = tonic-clonic seizure.
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Table 1 Clinical findings
Pt Sex/agea
Epilepsy Motor and cognitive developments
Onset/outcome
Epilepsy treatment; (+)
effective, (2) not effective Genetic mutationOnset Sz type Sz duration
Sz frequency/
clusters Before After epilepsy onset
1 M/21 y 3 y T → clon <20 min Daily/no Delay,
dystonia
Severe ID, no SP/EC,
quadriparesis, dyskinesia
Gradual/(6 y) sz
exacerbation, then
stable
(+) VPA, CBZ, GVG, CLB, CNZ,
LTG, CBZ, ESM; (−) LEV, TPM,
FLB, ZNS, PHT, predn
c.1201T>C, p.Tyr401His
2b M/3 y, 10 mo 4 mo T, Sp 3 s to 1 min Daily/yes Delay Severe ID, no SP/EC,
hypotonus, hypokinesia
Gradual/progressive
wors
(−) VGB, TPM, CLB, predn, keto
diet
c.1228G>T, p.Val410Leu
3c M/(†) 22 mo 1¼
mo
FS Rarely
prolonged
Daily (stretch)/
yes
Severe
delay
Severe ID, no SP/EC, EM,
dyskinesia, PEG
Stormy/progressive
wors until dead
(+) OXC, PHT; (−)multiple AEDs c.2300C>T, p.Thr767Ile
4 F/25 mo 5½
mo
FS, Sp, TCS <40 s/SE Daily to
monthly/yes
Hypotonus Severe ID, no SP/EC,
hypotonus, dyskinesia
Acute/poor
acquisitions
(+) CLB, OXC, VPA; (−) LEV,
TPM, PB
c.2549G>T, p.Arg850Leu
5 M/10 y, 7 mo 1 mo T,
hemiclonic,
TCS
30–40 s/SE Monthly/yes Hypotonus
interm EC
Severe ID, no SP/EC, hypo/
hypertonus, dyskinesia
Stormy/rare sz since
age 5 y
(+) CBZ, PHT; (−) LEV, TPM, PB c.2590C>G, p.Leu864Val
6b F/9 y, 9 mo 2½
mo
FS, Sp, TSC 10 s to 3
min/SE
Monthly to
weekly/yes
N Severe ID, no SP/EC, hypo/
hypertonus, EM, PEG
Stormy/wors until age
6 y, then stable
(+) OXC, TPM, CLB, ZNS; (−) PB,
GVG, LEV, predn
c.2879T>A, p.Val960Asp
7 M/27 mo 4 mo T → clon,
Sp, FS, TCS
0.5–2 min/
SE
Daily to
monthly/yes
N Severe ID, no SP/EC,
hypotonus, dyskinesia
Stormy/progressive
wors
(+) CBZ, TPM, PB, GVG, ACTH;
(−) LEV, VPA, PHT
c.2932A>G, p.Ser978Gly
8b F/7 y, 9 mo 10 mo FS, T,
hemiclonic
<60 min/SE Monthly to
weekly/no
Delay Severe ID, no SP, hypotonus,
dyskinesia, PEG
Gradual/progressive
wors
(−) VPA, LEV, LTG, OXC, CLB,
STP
c.4419+1_+4del, Pro1428_
Lys1473del (pred)
9 M/24 mo 4 mo T, FS, GTC 1–2 min/SE Every 3 mo/
yes
Hypotonus Moderate ID, SP delay,
hypotonus dyskinesia, tremor
Stormy/progressive
wors, now stable
(+) PHT, CBZ (−) LEV c.4423G>A, p.GLy1475Arg
10 M/5 y 6 mo TCS 1–6 min/SE
(refractory)
Monthly →
now sz-free/
no
N Moderate ID, motor + SP
delay, normal EC, PEG
Gradual/better from
age 5 y
(+) PB, OXC, LCS, CLB; (−) LEV,
ZNS, VPA
c.4423G>A, p.Gly1475Arg
11 F/3 y, 9 mo 4½
mo
Asym T→
clon
2 min/
subsequent
sz
Daily→ now
sz-free/no
N/mild
delay
Moderate/severe ID, no SP,
interm EC, progr microcrania
Stormy/progressive
wors
(+) CBZ CLB, GVG, TPM, predn,
keto diet; (−) LEV, VPA
c.4423G>A, p.Gly1475Arg
12 F/19 mo 3 wk T 3–5 min/SE Monthly/yes Hypotonus Severe ID, no SP/EC, hypo/
hypertonus
Stormy/severe drug-
resistant epilepsy
(+) PHT, MDZ (SE); (−) CBZ, LZP,
VPA, LEV, LCS, PB, CBD
c.4472C>T, p.Ala1491Val
13 M/(†) 26 mo 1 mo T, TCS 2 min/SE 50–200 d→
monthly/yes
Delay Severe ID, no SP/EC,
hypotonus, PEG
Stormy/progressive
wors
(+) LCS; (−) PB, PHT, LEV, OXC,
TPM, CBD, keto diet
c.4472C>T, p.Ala1491Val
14 F/15 y, 10 mo 2 mo FS, MA,
clon, TCS
5 s to 2 min/
SE
Weekly/no Delay Severe ID, no SP, good EC, EM Stormy/wors until age
9 y, then stable
(+) STP, keto diet c.4493A>T, p.Lys1498Met
Continued
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Table 1 Clinical findings (continued)
Pt Sex/agea
Epilepsy Motor and cognitive developments
Onset/outcome
Epilepsy treatment; (+)
effective, (2) not effective Genetic mutationOnset Sz type Sz duration
Sz frequency/
clusters Before After epilepsy onset
15 F/3 y, 10 mo 3½
mo
FS, Tv, Sp,
TCS
2–8 min Monthly/yes N (jerks) Severe ID, no SP/EC, EM, hypo/
hypertonus, dyskinesia, PEG
Stormy/regression
and progressive wors
(+) TPM, VPA, CLB, STP, PB,
ESM, CLN, CBZ, PHT; (−) CNZ,
CLB, predn
c.4594A>T, p.Ile1532Phe
16 M/22 y 15 d FS, T, Sp,
TCS
few s to 2
min/SE
Monthly/yes N (lateral
eye
movement)
Severe ID, no SP/EC, EM,
hypotonus, dyskinesia
Stormy/wors until age
7 y, than ↓ sz freq
(+) VPA, PB, VGV, PHT, TPM,
LTG,NZP, FBM, ZNS, RFM, keto
diet
c.4639T>G, p.Phe1547Val
17b F/(†) 23 mo 5½
mo
FS, TCS 3–15 min/SE Monthly/yes N Severe ID, no SP/EC, EM,
hypotonus, dyskinesia
Gradual/progressive
wors until dead
(+) VPA, CNZ, ZNS, ETS, TPM;
(−) LTG, LEV, keto diet
c.4850G>A, p.Arg1617Gln
18c F/8 y 3 mo Asym T/Tv,
FS, TCS
1–2 min/SE Several per
day →
monthly/yes
Hypotonus Severe ID, interm EC, no SP,
hypo/hypertonus, dyskinesia,
PEG
Stormy/wors until 5 y,
then stable
(+) CBZ, PHT, PRM, predn; (−)
LEV, LCS, STP, PB, TPM, ZNS,
keto diet
c.4948G>A, p.Ala1650Thr
19c F/9 y 4 mo FS, TCS 5–10 min/SE Several per
day/yes
Delay Severe ID, no SP/EC,
quadriparesis, dyskinesia
Gradual/progressive
wors
(+) CBZ, PB, VPA, PRP, CLB,
predn, LCM, keto diet; (−) LEV
c.4948G>A, p.Ala1650Thr
20 M/15 y 11½
mo
T, Tv→ clon s to 10 min/
SE
Weekly/yes Hypotonus
dystonia
Moderate/severe ID, no SP,
poor EC, dystonia, EM,
hypotonus, microcrania
Stormy/wors until age
7 y, then stable
(+) PHT, CLB, DZP, predn c.5292C>G, p.Ile1764Met
21b F/(†) 5 y 4 mo FS, asym T/
Tv, Sp, TCS
<40 min/SE Monthly/yes N Severe ID, no SP/EC, EM, PEG Stormy/progressive
wors until dead
(+) PB, VPA, LTG, TPM, CLB,
OXC, DZP, keto diet; (−) LEV,
RFM
c.5614C>T, p.Arg1872Trp
22c M/2 y, 9 mo 3 mo FS→ T, TSC <20 min Daily/no Mild delay Moderate/severe ID, no SP,
progressive microcrania
Stormy/progressive
wors
(+) TPM, VPA, PHT, CLB, STP,
PB, ESM, CLN, CBZ
c.5614C>T, p.Arg1872Trp
Abbreviations: ACTH = adrenocorticotropic hormone; AEDs = antiepileptic drugs; asym=asymmetric; CBD = cannabidiol; CBZ = carbamazepine; CLB = clobazam; clon = clonic; CNZ = clonazepam; EC = eye contact; EM = epileptic
myoclonus; ESM = ethosuximide; freq = frequency; FLB = felbamate; FS = focal seizure; GVG = gamma-vinyl GABA; ID = intellectual disability; interm = intermittent; keto = ketogenic; LEV = levetiracetam; LTG = lamotrigine; MA =
myoclonic absences; N = normal; PEG = percutaneous endoscopic gastrostomy feeding tube; PHT = phenytoin; predn = prednisolone; PRP = perampanel; pt = patient; SE = status epilepticus; Sp = spasm-like episodes; SP =
speech language; STP = stiripentol; sz = seizures; T = tonic; TCS = tonic-clonic seizures; TPM = topiramate; Tv = tonic vibratory; VPA = valproic acid; wors = worsening; ZNS = zonisamide.
a Age at latest investigation.
b Larsen et al., 2015.
c Same patient described in references 8 and 15 (no clinical information reported).
†Deceased.
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myoclonic jerks from birth. The most common seizure types
at epilepsy onset were tonic, tonic-vibratory, and tonic-clonic
(18/22), often asymmetric or lateralized (7/22), and pre-
ceded by cyanosis or autonomic features (9/22). One patient
(7) had nonconvulsive status epilepticus (NCSE) at epilepsy
onset. Two patients debuted with subsequent “convulsive”
afebrile seizure (15, 22) and 2 had epileptic spasms with
hypsarrhythmia at onset (2, 4).
Over the course of the disease, all patients developed motor
and nonmotor FS including focal to bilateral tonic-clonic
seizures (TCS) (17/22), spasm-like episodes (8/22 [36%]),
and erratic myoclonus (8/22 ([36%]). In 18 of 22 patients
(82%), seizures were prolonged (up to 20 minutes), often
requiring acute benzodiazepine administration, and, in some
cases, resuscitation because of severe oxygen desaturation
(9, 19, 22). In 16 of 22 patients (73%), seizures clustered
over 2 to 3 days (table 1), often ending with one or more
generalized TCS. Seizures occurred most often during sleep;
this was very frequently reported from children’s caregivers
and from clinical charts. In 8 patients, this ﬁnding was
conﬁrmed by prolonged video-EEG recordings, including
all-night sleep. According to the clinical reports, seizures
might have also been exacerbated during febrile/afebrile
illness in 7 patients (31%) (4–6, 15, 17, 20, 22) and after
sleep deprivation or on (provoked) awakening in 4 (18%)
(1, 15, 18, 22). Fourteen patients (64%) had episodes of
NCSE, in 7 of them with myoclonic features. In 2 patients (7
and 12), NCSE was drug-refractory and followed by severe
worsening of the neurologic status.
Epilepsy was poorly controlled in all but 4 patients (5, 9, 10,
11) despite combinations of 2 to 3 AEDs and trials of 3 to 14
AEDs per patient. The most eﬀective AEDs were phenytoin,
carbamazepine, and oxcarbazepine (table 1), usually at
supratherapeutic doses. Benzodiazepines (clobazam, di-
azepam, midazolam) were eﬀective in halting seizure clus-
ters in 15 of 22 children (68%). Levetiracetam was tried in
15 patients, with poor eﬀect, if any, in 13 patients and sei-
zure exacerbation in 2. Inconsistent seizure improvement
was observed with other sodium channel blockers (lamo-
trigine, eﬀective in 3/5 patients; topiramate eﬀective in 8/14
patients). Zonisamide was eﬀective in 5 of 6 patients (6, 10,
16, 17, 18). Single patients experienced transient beneﬁt on
stiripentol (3/5 children; in patient 14, for generalized
TCS), lacosamide (1/3 children; patient 10), ruﬁnamide
(patients 16 and 21), and perampanel (patient 18). In one
patient (16), felbamate exacerbated his movement dis-
orders. Spasms improved on high-dose prednisolone/
adrenocorticotropic hormone (8/8 patients, lost eﬃcacy
in 4 of them) and vigabatrin (4 patients). One patient (4)
had severe hypotonia, respiratory insuﬃciency, and som-
nolence on prednisolone and vigabatrin, with no beneﬁt for
her spasms. The ketogenic diet was eﬀective in 5 patients
(used acutely to stop NCSE in patient 14); no improvement
was observed in 4. Cannabidiol was tried in 2 children (12,
13) without beneﬁt.
Other neurologic findings
Sixteen patients (73%) had mild to moderate developmental
delay since birth. Other neurologic signs (table 1) predated
epilepsy onset in 5 patients (23%) (1, 5, 15, 16, 20). Epilepsy
onset was associated with cognitive decline in all. Twenty of 22
children (91%) had severe to profound intellectual disability
when last seen. Speech was absent in 20 patients (91%) and
delayed in 2 patients (9, few words; 10, simple sentences).
Seventeen patients (77%) developed progressive cortical visual
impairment, initially intermittent in relation to seizure clusters,
and nystagmoid eye movements. Other common neurologic
features included axial hypotonia (14 patients [64%]),
quadriplegia/limb spasticity (11 patients [50%]), extrapyramidal
or cerebellar signs (dystonia, choreoathetosis, dyskinesia, clum-
siness, poor coordination) (12 patients [55%]), and myoclonus
(8 patients [36%]). Four patients (18%) developed progressive
microcephaly (11, 20, 22) or decelerating head growth velocity
(4). One child (5) had intermittent nonepileptic diaphragmatic
myoclonus. Gastrointestinal disorders were reported in 18 of 22
patients (82%), ranging from sialorrhea (3 patients) to severe
gastroesophageal reﬂux, constipation, and inadequate or unsafe
oral feeding (15 patients). Eleven children (50%) required
a percutaneous endoscopic gastrostomy feeding tube. Sponta-
neous bone fractures were reported in 2 patients (9%) (16 and
20). Dysmorphic features were not observed.
Epilepsy, cognitive decline, and neurologic signs had a stormy
onset and progressive worsening in 16 of 22 patients (73%).
The remaining 6 children (27%) followed a more gradual
course, with periods of stagnation and regression associated
with increased seizure frequency, alternating with partial re-
covery during seizure-free periods.
Four patients (18%) (3, 13, 17, 21) died between age 22months
and 5 years 6 months. Before dying, all 4 had uncontrolled
seizures and progressive severe neurologic deterioration; 3 suc-
cumbed to a lower respiratory tract infection (3, 13, 21). Patient
17 died in a terminal phase of her disease, after extreme wors-
ening of her epilepsy and general condition the last year of life.
Among older patients, aged 6–22 years (10/22), 8 stabilized or
improved overall with age, with better seizure control, from age 5
to 9 years. One child (9), with stormy epilepsy onset at the age of
4 months, showed a milder evolution from 2 years of age.
EEG and other neurophysiologic investigations
Interictal EEG at epilepsy onset was normal in 7 of 20 patients
(35%), showed discrete slowing and infrequent epileptiform
abnormalities in 10 (40%), hypsarrhythmia in 2, and NCSE in
one. All patients developed progressive background slowing
and multifocal epileptiform abnormalities, occurring asyn-
chronously, predominantly in the temporo-parieto-occipital
regions, either at epilepsy onset (6/20 [30%]) or after 1 to 7
months (14/20 [70%]). EEG abnormalities consisted of high-
amplitude sharp waves and trains of delta and beta activity,
increased during sleep (ﬁgure 1). The progressive increase of
posterior temporo-occipital beta/delta activity paralleled
worsening of visual impairment. Source analysis indicated
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a generator deep in the occipitoparietal regions (ﬁgure 1). An
overnight sleep EEG was recorded in 10 patients, revealing
a regularly organized sleep macrostructure.
Seizures were captured on video-EEG in 21 of 22 patients. FS
were the most common seizure type. We did not record any
true generalized TCS, only focal-to-bilateral TCS, and the
reported “absence” seizures were all FS, except for patient 14,
who had myoclonic absences from age 10 months. FS were
typically prolonged, lasting up to 20 minutes, with (1) prom-
inent hypomotor and autonomic symptoms (ﬂushing, tachy-
cardia, and/or bradycardia), often with lateral eye deviation,
mouth or eyelid myoclonia, apnea, and cyanosis, followed at
times by (2) asymmetric tonic or tonic-vibratory phase and (3)
prolonged clonic or hemiclonic manifestations with or without
(4) bilateral TCS (ﬁgure 2 and video 1). The hypomotor phase,
which often passed unnoticed, could lead directly to a bilateral
TCS. The EEG correlate of FS showed 2 spread patterns: (1)
posterior temporal rhythmic activity (at seizure onset and end),
with slow spread sometimes with intraictal migration from one
hemisphere to the other or, less frequently, (2) diﬀuse EEG
desynchronization, followed by posterior rhythmic spiking and
spreading to the frontocentral regions (ﬁgure 2).
In 7 children (32%), we documented episodes resembling
spasms, often asymmetric and followed by hyperkinetic
manifestations (5–10 seconds) (video 2). They were recor-
ded during both wakefulness and sleep, occurring in-
dependently or in clusters after an FS. The EEG correlate was
diﬀuse low-voltage fast activity, sometimes preceded by
a high-voltage sharp and slow wave complex, consistent with
a tonic seizure pattern (ﬁgure 3A). Seven patients (32%) had
segmental erratic jerks, consistent with cortical myoclonus,
often occurring almost continuously (ﬁgure 1). Two patients
also had tongue (3) and laryngeal myoclonus (16). In 5
patients, we recorded myoclonic NCSE, with an EEG corre-
late consisting of triphasic sharp waves predominant in the
central or rolandic regions (ﬁgure 3B). Two children had
Figure 1 Interictal EEG
Interictal EEG of patients 2 (15 months), 4 (18 months), 7 (8 months), 17 (23 months), 15 (10 months), and 6 (23 months) showing common features of (1)
background slowing, (2) blending of polymorphic delta andbeta activity (18–20Hz), usually in trains of 200–600milliseconds (see patient 17), and (3)multifocal
spike and waves, predominant in the posterior temporal and parieto-occipital regions bilaterally asynchronously. Patient 15: Both beta activity and the
epileptiform abnormalities have an accentuation and diffuse spreading during sleep. Concomitantly with the anterior spreading of the epileptiform ab-
normalities, discrete rhythmic myoclonic jerks (7–8 Hz) appeared. EEG parameters: sensitivity 100 μV/mm, band-pass filter 1–70 Hz. Patient 6: Discrete,
subcontinuous beta and delta activity and spike/polyspikes-and-waves in the right posterior temporo-occipital regions or diffuse, with frontal predominance,
but posterior onset, as shown on the amplitudemaps below the EEG. The source analysis of the beta activity (below the EEG trace) indicated a generator deep
in the occipitoparietal regions. EEG parameters: sensitivity 150 μV/mm, band-pass filter 1–50 Hz.
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recurrent paroxysmal autonomic manifestations with hyper-
ventilation, sweating, tachycardia (patient 3), or change of
pupil size (patient 4), without EEG correlate.
Electroretinograms were normal in 4 of 5 cases (11, 12, 16,
21) and low amplitude in one (7). Visual evoked potentials
were normal in 4 patients (1, 6, 12, 16), showed reduced
amplitude in 2 (7, 18), and increased latency in 2 (7, 14).
Somatosensory evoked potentials were normal in 3 patients
(1, 6, 11) and extinct in one (14). Sensory and motor nerve
conduction studies in 2 children (5, 8) were normal.
MRI findings
In 20 of 22 patients (91%), cerebral MRI was normal or
showed minor abnormalities at epilepsy onset. Two (13, 21)
hadmild brain atrophy at age 10months. In 10 patients (45%)
(1, 3–7, 10–12, 16), follow-up MRI scans showed progressive
cortical and subcortical atrophy (ﬁgure 4, patient 3). One
patient (4) had sequelae of a choroid plexus and cerebellar
hemorrhage. In 3 patients (3, 4, 16), hyperintensity of the
posttrigonal white matter on T2-weighted imaging was seen,
along with restricted diﬀusion in the optic radiations (ﬁgure 4,
patients 4 and 16). Magnetic resonance spectroscopy was
abnormal in 2 of 6 patients, showing nonspeciﬁc posterior
abnormalities (patient 7) or a reduced N-acetylaspartate/
creatine ratio, and increased choline/creatine ratio in the
parietal retroventricular white matter, likely due to cell
membrane turnover (ﬁgure 4, patient 16).
Genetic investigations
Twenty-one of 22 patients (95%) carried a de novo hetero-
zygous missense variant in SCN8A (table 1). We identiﬁed 16
diﬀerent missense variants; all were predicted to be damaging
by one or more prediction tools (PolyPhen-2, SIFT, Muta-
tionTaster) and absent in control databases (ExAC, gnomAD).
Patient 8 carried a de novo splice-site variant, predicted to cause
the inframe deletion Pro1428_Lys1473del and absent in con-
trol databases (ExAC, gnomAD). The splice-site variant and 9
Figure 2 Ictal EEG
(A) Patient 6 (23months): subtle focal seizure (duration: 19150) during sleep, with polypnea, and tachycardia, tonic asymmetric posturing (right arm flexed), eye
deviation to the right, discrete flushing, and blinking. This EEG shows a right occipital and posterior temporal onset and propagation. Clinical manifestations:
(a) Staring, (b) Irregular breathing, (c) Tonic asymmetric phase, (d) Agitation/polypnoea. EEGparameters: sensitivity 150μV/mm, band-pass filter 1.6–50Hz. (B)
Patient 15 (10months): prolonged tonic-vibratory and clonic seizure during sleepwith subtle, unrecognized onset (duration: ca. 49500). Clinicalmanifestations:
(a) arousal and staring, mild polypnea (ca. 19) followed by frequent blinking and eyelid myoclonia (ca. 500), (b) deviation of head and eyes to the left and
asymmetric tonic posturing (right arm flexed) (180), then crying and (d) clonic-vibratory phase (ca. 350) and (d) clonic jerks. The seizure ends with staring eye
deviation to the left, eyelidmyoclonia, and irregular breathing and chewing (d). During the first part of the seizure (a), the EEG shows only a discrete slowing in
the right posterior quadrant (maximum occipital), evolving into posterior rhythmic rapid activity (right > left) (b) and diffuse spike-and-slow waves (c and d).
The seizure ends focally in the occipital and posterior temporal regions (e). EEG parameters for (A) and (B): sensitivity 150 μV/mm, band-pass filter 1.6–50 Hz.
These seizures are shown in video 1.
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of themissense variants have been previously published.8,9,14–16
Seven missense variants (p.Tyr401His, p.Arg850Leu,
p.Leu864Val, p.Ala1491Val, p.Lys1498Met, p.Phe1547Val,
p.Ile1764Met) have not been previously reported (ﬁgure 5).
Discussion
We report a description of the phenotype of EIEE related to
de novo heterozygous variant in SCN8A (EIEE13, OMIM
#614558).
Twenty-one of 22 patients had a missense variant, whereas
one (previously published) patient had a de novo splice-site
variant, whose predicted product is a frame deletion. Seven
missense variants have not previously been associated with
SCN8A-DEE, 5 of them being located into domains relevant
to protein function (ﬁgure 4). Nine of the missense variants17
have been previously described.8,9,14–16However, 4 patients with
these mutations are unpublished (3, 18, 19, 22). Four missense
variants recurred in 2 to 3 patients each in the present study
(p.GLy1475Arg, p.Ala1491Val, p.Ala1650Thr, p.Arg1872Trp).
Figure 3 Episodes resembling spasms, and myoclonic NCSE
(A) Video-EEG-polygraphic recordings in patient 6 (6 years, 6 months), showing a cluster of episodes resembling spasms, followed by mild hyperkinetic
behaviors, corresponding to diffuse EEG flattening followed by discrete slowing in the occipital regions. These polygraphic recordings correspond to the
spasm-like events shown in video 2. EEG parameters: sensitivity 300 μV/mm, band-pass filter 1.6–50 Hz. (B) EEG-polygraphic recordings in patient 21 (4 years,
1 month) showing (a) accentuation of the myoclonus and perturbation of consciousness for several hours, consistent with myoclonic NCSE. The EEG shows
continuous rhythmic activity with superimposed high-amplitude sharpwaves, in the left fronto-central region and the vertex. (b) After benzodiazepine (buccal
midazolam [MDZ]): resolution of the symptoms and reappearance of the interictal epileptiform abnormalities in the temporo-parieto-occipital region. EEG
parameters: sensitivity 300 μV/mm, band-pass filter 1–70 Hz. NCSE = nonconvulsive status epilepticus.
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We could not ﬁnd evident genotype-phenotype correlations,
both among the present group of patients and compared with
the benign cases previously described.3
From birth, 73% of patients had developmental delay and/or
other neurologic signs (23%). Epilepsy onset, at a median age
of 4 months (range 1–36 months), was typically stormy
(73%), but a more gradual and progressive course was also
seen (27%). The ﬁnding of rhythmic fetal or neonatal ab-
normal movements in 2 children suggested a possible prenatal
subtle onset of epilepsy or movement disorder.18
The interictal EEG was normal or mildly abnormal in 91% of
patients at epilepsy onset, then deteriorated, as observed pre-
viously,9 recapitulating the murine model (heterozygous
Scn8aN1768D/+ mice).19 Despite the severe evolution of the
disease, the interictal EEG was often normal or almost normal
for several months after epilepsy onset.20 With time, multifocal
interictal epileptiformdischarges, predominantly in the posterior
quadrants, together with progressively increasing delta activity
with superimposed bursts of beta activity appeared, as observed
previously.9 This peculiar EEG pattern (ﬁgure 1) has not been
reported in SCN2A-related epileptic encephalopathy and diﬀers
from EEG abnormalities in epilepsy syndromes within the
generalized epilepsy with febrile seizures plus spectrum with
SCN1A mutations,21 and might be a marker of EIEE13.
The source analysis of the beta-delta activity suggests a gen-
erator deep in the occipitoposterior temporal regions. In a few
patients with cortical visual impairment, the MRI showed
a restriction and hyperintensity of the visual tract and the
magnetic resonance spectroscopy an alteration at the level of
the retroventricular white matter, reﬂecting neuroaxonal
damage and abnormal cellular membrane turnover, as in the
Figure 4 MRI findings
(A) Patient 3: Axial T2-weighted MRI showing pro-
gressive cortical and subcortical brain atrophy
from age 2 to 12 months. (B) Patient 4: Axial
T2-weighted MRI showing mild frontotemporal at-
rophy, hyperintensity (arrow), and progressive re-
striction in optic radiations from age 6 to 9months.
(C) Patient 16: Axial T2-weighted (a), sagittal T1-
weighted (b), coronal inversion recovery (c), and
single voxel spectroscopy study (d) at echo time =
144 milliseconds in the left posterior hemispheric
white matter. Conventional MRI (a, b, c) shows
frontal lobe hypoplasia (a, b), hypoplasia of the
posterior segment of the corpus callosum (b),
mainly at the level of the splenium and of the ver-
mis (b). Dysmorphism/dysplasia of the mesial
temporal regions is also evident (c), predominantly
on the left side, as well as linear medial hyper-
intensity of the pallidi (a) of uncertain significance.
Magnetic resonance spectroscopy (d) shows re-
duced N-acetylaspartate (NAA)/creatine (Cr) ratio,
due to aspecific neuroaxonal damage, and in-
creased choline (Cho)/Cr ratio, likely due to cell
membrane turnover.
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case of demyelination and gliosis (ﬁgure 4, patients 4 and 16).
Likewise, in infants with perinatal brain lesions and in children
with West syndrome, the visual impairment correlates better
with the EEG than with the brain MRI ﬁndings.22,23
In contrast to the description of a disturbed sleep pattern in
the homozygous null mice lacking functional NaV1.6,24 we
failed to document alterations of sleep macrostructure. The
disease mechanisms of the homozygous loss-of-function mice
are probably diﬀerent from the heterozygous, likely gain-of-
function pathogenic variants in our patients.
Video-EEG recordings documented FS with posterior EEG
onset and slow spreading, sometimes with intraictal migration
of the epileptic discharge from one hemisphere to the other.
The early clinical semiology included (1) hypomotor and
autonomic symptoms, eye deviation, and often cyanosis,
eventually evolving to (2) asymmetric tonic and (3) (hemi)-
clonic manifestations with or without (4) bilateral TCS. All
recorded TCS were focal onset seizures that became bilateral;
in some cases, seizure onset was not recognized. FS were often
misclassiﬁed as absences, tonic, or generalized tonic-clonic
seizures, or even unrecognized, depending on the prominence
of motor manifestations. True myoclonic absence seizures
were recorded in only one patient (14). The mouse model of
SCN8A-related epilepsy exhibits diﬀuse spike-waves and ab-
sence epilepsy, suggesting that SCN8A might cause general-
ized epilepsy as well.25 Children with SCN8A-DEE have been
reported as having both FS and generalized seizures.8,9 Here,
we classiﬁed seizures based on video-EEG recordings, doc-
umenting focal to bilateral TCS, without true generalized
TCS. We therefore conclude that SCN8A-DEE presents as
a (multi)focal encephalopathy rather than a generalized one.
In a few patients, we observed intraictal migration of the FS
from one hemisphere to the other, similar to what is observed
in SCN2A encephalopathy.26 FS were characterized by pos-
terior temporo-occipital onset and oﬀset, very long duration
(several minutes), and clustering. NCSE was also common
(64%), often having a myoclonic component. These features
have not been previously described and might be character-
istic of, although not speciﬁc to, SCN8A-DEE.
Cortical myoclonus (36%) and clusters of spasm-like episodes
(36%) (ﬁgure 3) were relatively common features in SCN8A-
DEE. This is recapitulated in the mouse model of SCN8A-
DEE that shows diﬀuse spike- or polyspikes-and-slow wave
discharges, often accompanied by spasms or myoclonic
jerks.19
All seizures were extremely drug-resistant, with only 2
patients achieving periods of seizure control. The most ef-
fective AEDs were phenytoin, carbamazepine, and oxcarba-
zepine, usually at supratherapeutic doses. Both seizure
clusters and NCSE were responsive to benzodiazepines.
Levetiracetam was constantly ineﬀective or even worsened
seizures. The ketogenic diet was somewhat eﬀective in 5 of 9
patients (55%), and in one patient succeeded in interrupting
refractory NCSE. Thus, the ketogenic diet, eﬀective in 75% of
patients with Dravet syndrome,27 is also valuable in SCN8A-
DEE. Steroids provided some beneﬁt acutely and for control
of spasms. Cannabinoids were tried in 2 children, with no
eﬀects.
In all patients, seizure onset was followed by developmental
regression, with eventual severe to profound intellectual dis-
ability, absent speech (91%), worsening pyramidal/
extrapyramidal signs, dystonia and choreoathetosis (55%),
progressive visual impairment resulting in cortical blindness
(77%), and severe gastrointestinal problems (68%) with en-
teral feeding (45%). Progressive microcephaly and sponta-
neous bone fractures were occasionally reported. Recently,
bone loss syndrome with elevated bone reabsorption has been
associated with SCN8A-DEE.28 These clinical features are
distinguishable from most of the other common genetic
Figure 5 Gene structure and position of pathogenic variants
Four-domain structure of the voltage-gated sodium
channel α subunit, with transmembrane segments 1–4
forming the voltage sensor domain and segments 5 and
6 forming the pore region with its pore-forming loop.
The inactivation gate is located between trans-
membrane domain 3 and 4. All the pathogenic variants
identified in this study are indicated, and the 7 novel
variants are underscored: p.Ala1491Val (patients 12 and
13) and p.Lys1498Met (patient 14) affect the inactivation
gate, p.Tyr401His (patient 1), p.Ile1764Met (patient 20)
affect the transmembrane segment S6 of the DI and the
DIV, respectively, essential to form the intracellular
mouth of the pore, and p.Arg850Leu (patient 4) placed
in the S4 helix of the DII, involved in voltage sensitivity,
p.Leu864Val (patient 5) and p.Phe1547Val (patient 16)
are located in highly conserved regions of the gene. The
recurrent mutations (founded in 2–3 patients with
SCN8A developmental and epileptic encephalopathy
[references 8 and 9 and the present report]) aremarked
with a star.
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Table 2 Electroclinical features of the most frequent genetic causes of developmental and epileptic encephalopathies
Mutation
Phenotypes
(median age
at onset)
Mutation type
(function) Seizure type EEG features Cognition
Other
neurologic
features
Sz outcome (most
effective AEDs)
Additional
features
Other
associated
phenotypes
SCN8A (present report,
Larsen et al.,9 2015)
Severe DEE (4
mo); Milder
epilepsy (<1 y)
Missense (GOF) F (aut feat) + EM + Sp
+ TCS/clusters
BG slowing,
posterior delta/beta
activity and SW
Severe ID Quadriplegia,
cortical blindness,
dyskinesia, ataxia
Drug-resistant (CBZ,
OXC, VPA)
Dysphagia (PEG),
cortical blindness,
spontaneous
fractures
BFIS/ICCA
ID, ASD
SCN1A (Bureau and
Dalla Bernardina,21
2011) (Sadleir et al.,33
2017)
Dravet sd; EOEE Missense/
truncating
(LOF)
Hemiclonic
(alternating) + F + AA
+ TCS + febrile
seizures
BG slowing, theta
vertex/rolandic reg
diff polySW (max FC)
Moderate
ID; Severe-
profound
ID
Hypotonia, ataxia,
crouch gait
(VPA, CLB, STP, TPM,
keto diet, CBD,
fenfluramine); Sodium
channel blockers to be
avoided
Autistic features,
ADHD, SUDEP
GEFS+,
familial
migraine
SCN2A (Wolff et al.,29
2017)
EOEE, Ohtahara
sd (<3 mo);
EIMFS (>3 mo)
Missense
(GOF);
Missense/
truncating
(LOF)
F + Sp; F (aut feat) +
Sp + T + hemiclonic
BG slowing,
multifocal
epileptiform abn,
ESES-like pattern
Severe ID Hypotonia, ataxia Sz-free/reduction
(PHT, OXC, CBZ); Drug-
resistant
Dysphagia (PEG) BFIS, ASD,
MAE, ESES-
like
STXBP1 (Stamberger
et al.,34 2016)
EOEE (6 wk);
Otahara sd →;
West sd, Dravet
sd
Truncating/
missense (LOF)
Sp + F + T Burst-suppression
pattern,
hypsarrhythmia
Severe to
profound
ID
Pyramidal,
extrapyramidal,
cerebellar signs,
dyskinesia
33% patients sz-free
(VPA, LEV, GVG)
Autistic features ID, ASD
KCNQ2 (Weckhuysen
et al.,35 2012)
EOEE (neonatal
<3 mo)
Missense (GOF) T (apnea) + clon +
EM + Sp + TCS
BG slowing,
multifocal
epileptiform abn
Mild to
profound
ID
Hypo/hypertonus,
dystonic fits
Variable degree of
drug resistance (CBZ,
PHT)
Ictal bradycardia,
SUDEP
BFNS
Abbreviations: AA = atypical absences; abn = abnormalities; ADHD = attention-deficit/hyperactivity disorder; AEDs = antiepileptic drugs; ASD = autism spectrum disorders; aut feat = autonomic features; BFIS = benign familial
infantile seizures; BFNS = benign familial neonatal seizures; BG = background; CBD = cannabidiol; CBZ = carbamazepine; CLB = clobazam; clon = clonic; DEE = developmental and epileptic encephalopathy; Diff = diffuse; EIMFS =
epilepsy of infancywithmigrating focal seizures; EM=epilepticmyoclonus; EOEE = early-onset epileptic encephalopathy; ESES = encephalopathywith status epilepticus during sleep; F = focal seizures; FC = fronto-central; GEFS+
= generalized epilepsywith febrile seizures plus; GOF = gain of function; GVG = gamma-vinyl GABA; ICCA = infantile convulsions and paroxysmal choreoathetosis; ID = intellectual disability; keto = ketogenic; LEV = levetiracetam;
LOF = loss of function; MAE =myoclonic atonic epilepsy; max =maximum; OXC = oxcarbazepine; PEG = percutaneous endoscopic gastrostomy feeding tube; PHT = phenytoin; Reg = regions; Sp = spasms; sd = syndrome; STP =
stiripentol; SUDEP = sudden unexpected death in epilepsy; SW = spike and slow waves; T = tonic; TCS = tonic-clonic seizures; TPM = topiramate; VPA = valproic acid.
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causes of DEE (table 2 for an overview) and bear some
similarity with those of SCN2A encephalopathy.29 Cortical
blindness has not been described in SCN2A encephalopathy
but may be a common feature of severe encephalopathies with
diﬀerent etiologies.
During early childhood, 4 patients died in the context of
profound neurologic deterioration and uncontrolled daily,
prolonged seizures. Increased precocious death rate, because
of SUDEP, has been reported2,13,30,31 to occur in about 10%
of patients with SCN8A.12 Convulsive seizures leading to
cardiac arrest and ultimately to SUDEP have been docu-
mented in a mouse model with a gain-of-function SCN8A
mutation.32–35
In our cohort, we did not document “critical” ECG alterations
during the seizures, whereas irregular breathing, cyanosis, and
brady-/tachycardia were common. The prominent autonomic
ictal manifestations and the prolonged seizure duration with
frequent evolution to bilateral TCS may be risk factors for
ictal death. However, none of these deaths were unexpected.
Death occurred in early childhood, within a critical age (2–5
years) at which patients with SCN8A-DEE experience pro-
gressive worsening of their epilepsy and neurologic condition,
rendering them susceptible to respiratory distress. Un-
controlled epilepsy, severe neurologic compromise, and the
relentless severe inﬁrmity likely contributed to the fatal out-
come, suggesting that there are causes other than SUDEP for
death in SCN8A-DEE.
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